Nucleix
PrivateLast Round
Series C
Extension
Dec 31, 2021
Total Funding Raised
$143.45M
Company Overview
Nucleix operates in Healthcare & Life Sciences and is based in Israel. Its latest recorded funding round was a Series C Extension round in December 2021.
Nucleix is a biotechnology company that develops non-invasive molecular diagnostic tests to enhance the accuracy and effectiveness of cancer detection through the use of DNA methylation patterns and proprietary biomarker assays.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nucleix Comparables
Compare Nucleix with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pacific Edge Limited | 82% | |
| Pangea Laboratory | 81% | |
| MDxHealth | 78% |
For institutional investors. Book with your work email.
Nucleix Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Dec 31, 2021 | ||||
| Series C | Apr 7, 2021 | ||||
| VC Round | Jul 1, 2019 | ||||
| Grant | Jul 30, 2018 | ||||
| VC Round | May 23, 2016 | ||||
Grant | Mar 1, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nucleix Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aurum Ventures | Series C |
| DSC Investment | Series C Extension, VC Round, Series C |
| RA Capital Management | Series C Extension, Series C |
| European Commission (Horizon Europe) | Grant |
| LYFE Capital | Series C Extension, Series C |
| Gefen Capital | Series C |
| OrbiMed | VC Round, Series C Extension, Series C, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 25, 2025
Presenting Bladder EpiCheck data at the AUA 2025 conference.
- Dec 30, 2021
$22M round led by Sands Capital
For institutional investors. Book with your work email.
Nucleix Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nucleix's valuation, stock price, and market status.
Is Nucleix a public or private company?
Nucleix is a private company.
What is the current stock price of Nucleix?
Nucleix is a private company, so its shares have no public market price. Caplight tracks Nucleix's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nucleix worth (valuation)?
Valuation information for Nucleix is not publicly available.
Can I buy Nucleix stock?
Nucleix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nucleix's last funding round?
Nucleix's most recent funding round was Series C Extension on December 31, 2021.
Who are the main investors in Nucleix?
Key investors in Nucleix include RA Capital Management, OrbiMed, Aurum Ventures MKI, Sands Capital.
Will Nucleix IPO soon?
No public IPO plans have been announced for Nucleix.
How can I track Nucleix secondary market activity?
Caplight tracks bids, offers, and trades in Nucleix's shares on secondary markets.